As of January 22, 2025, Boundless Bio (BOLD) has a market cap of $57.311 million USD. According to our data, Boundless Bio is ranked No.8073 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $57.31 M |
-11.38%
|
Dec 31, 2024 | $64.67 M |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Pfizer
PFE
|
$147.40 B |
-0.003 M
|
USA
|
Merck
MRK
|
$242.04 B |
-0.000 M
|
USA
|
Bristol-Myers Squibb
BMY
|
$115.79 B |
-0.003 M
|
USA
|
Amgen
AMGN
|
$146.98 B |
0.004 M
|
USA
|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
Regeneron Pharmaceuticals
REGN
|
$74.73 B |
1.236 B
|
USA
|
Biogen
BIIB
|
$20.80 B |
0.000 M
|
USA
|
Moderna
MRNA
|
$14.82 B |
-0.000 M
|
USA
|
Novartis
NVS
|
$196.27 B |
-0.007 M
|
Switzerland
|
Sanofi
SNY
|
$129.14 B |
0.001 M
|
France
|
AstraZeneca
AZN
|
$211.49 B |
0.007 M
|
UK
|
GlaxoSmithKline
GSK
|
$68.21 B |
-0.002 M
|
UK
|
Eli Lilly
LLY
|
$678.07 B |
0.022 M
|
USA
|
Market Cap | = | BOLD Stock Price | * | BOLD Shares Outstanding |
= | $2.57 | * | 22.30 M | |
= | $57.31 M |